Mark A. T. Blaskovich

Mark A. T. Blaskovich

Centre for Superbug Solutions, The University of Queensland

Affiliated withThe University of Queensland

Research Area

Biography

Dr Mark Blaskovich is an antibiotic hunter based at the Centre for Superbug Solutions in the Institute for Molecular Bioscience at The University of Queensland. A medicinal chemist with 15 years of industrial drug development experience prior to his academic career, Mark has been developing new antibiotics to treat drug resistant pathogens and using modified antibiotics to detect bacterial infections. He is a cofounder of the Community for Open Antimicrobial Drug Discovery, a global antibiotic discovery initiative, and has led a number of UQ-industry collaborations focused on antibiotic development. An inventor on eleven patent families, Mark has developed drugs in clinical trials, published more than eighty research articles, and received over $10m in grant funding.

JoVE Journal Publications

ArticleTotal : 1
Year
Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
Publication title

Cited by 8

2020

Other Publications

Article
Year
Drug discovery and protein tyrosine phosphatases.

Current medicinal chemistry| PubMed ID: 19519384

2009
2014
Glycopeptide antibiotics: back to the future.

The Journal of antibiotics| PubMed ID: 25118105

2014
Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites.

European journal of medicinal chemistry| PubMed ID: 26117821

2015
Mucin Binding Reduces Colistin Antimicrobial Activity.

Antimicrobial agents and chemotherapy| PubMed ID: 26169405

2015
2016
2016
2016
Unusual Amino Acids in Medicinal Chemistry.

Journal of medicinal chemistry| PubMed ID: 27589349

2016
Helping Chemists Discover New Antibiotics.

ACS infectious diseases| PubMed ID: 27622818

2015
2016
2017
2017
2017
2017
2017
2017
2018
Developments in Glycopeptide Antibiotics.

ACS infectious diseases| PubMed ID: 29363950

2018
2018
2018
2018
2018
Silver bullets: A new lustre on an old antimicrobial agent.

Biotechnology advances| PubMed ID: 29847770

2018
Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?

Expert review of anti-infective therapy| PubMed ID: 29848132

2018
2018
2018
2019
2019
2018
Structure-Function Studies of Polymyxin B Lipononapeptides.

Molecules (Basel, Switzerland)| PubMed ID: 30717415

2019
2019
2019
2019
Non-antibiotic Small-Molecule Regulation of DHFR-Based Destabilizing Domains .

Molecular therapy. Methods & clinical development| PubMed ID: 31649953

2019
2020
Light-Activated Rhenium Complexes with Dual Mode of Action against Bacteria.

Chemistry (Weinheim an der Bergstrasse, Germany)| PubMed ID: 31788867

2019
Quinolone antibiotics.

MedChemComm| PubMed ID: 31803393

2019
Tyrosinase inhibitors as potential antibacterial agents.

European journal of medicinal chemistry| PubMed ID: 31810785

2020
Solid-Phase Synthesis of Octapeptin Lipopeptides.

Methods in molecular biology (Clifton, N.J.)| PubMed ID: 31879927

2020
2020